Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03690141 · ClinicalTrials.gov registry record · Phase 2
An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer
A Phase 2 study, sponsored by Effector Therapeutics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 16
- Enrollment target
NCT03690141 is a Phase 2 study that was terminated before completion, run by Effector Therapeutics. The registered enrollment target is 16 participants.
The verdict
NCT03690141, a Phase 2 study, was terminated before completion, sponsored by Effector Therapeutics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 16 participants
- Enrollment target
Study Summary
This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CRPC. An Open-label Study Examining the Effect of tomivosertib (eFT508) in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC)
Interventions
- DRUG eFT508
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2018-11-27 |
| Est. Completion | 2020-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03690141
The ClinicalTrials.gov registry entry for NCT03690141 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Effector Therapeutics, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which eFT508 is the first listed.
NCT03690141 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03690141 about?
NCT03690141 is a clinical study titled "An Open-label Study of the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer". This Phase 2 Open-label Study examines the efficacy, safety, tolerability, and pharmacokinetics (PK) of tomivosertib (eFT508) in Patients with advanced CRPC. An Open-label Study Examining the Effect of tomivosertib (eFT508) in Patients with Advanced Castrate-resistant Prostate Cancer (CRPC)
What is the current status of trial NCT03690141?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 16 participants. The study started on 2018-11-27. Estimated completion is 2020-04-27.
What interventions are being tested in trial NCT03690141?
The interventions under investigation include: eFT508 (DRUG).
Who is sponsoring clinical trial NCT03690141?
This trial is sponsored by Effector Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.